Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 5:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 3001–3024 of 3,984 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pathophysiology Clear all

Conditions: Primary Immunodeficiency (PID), Congenital Bone Marrow Failure Syndromes, Inherited Metabolic Disorders (IMD), Hereditary Anemias, Inflammatory Conditions, Systemic Juvenile Idiopathic Arthritis (sJIA), Juvenile Rheumatoid Arthritis (JRA)
Interventions: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa; Drug
Lead sponsor: Paul Szabolcs; Other
Eligibility: 2 Months to 55 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cerebral Palsy (CP), Stroke, Spinal Cord Injury, Traumatic Brain Injury, Charcot Marie Tooth Disease (CMT), Spina Bifida
Interventions: Participate in high intensity exercise of at least 20 minutes in 60 minutes session of RPE greater than 6.; Behavioral
Lead sponsor: University of Hartford; Other
Eligibility: 8 Years to 99 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: West Hartford, Connecticut

Conditions: Heat Strain, Healthy Volunteer Study, Kidney Dysfunction
Interventions: Vitamin B3; Dietary Supplement
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 45 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Acute Lymphoblastic Leukemia, Transcranial Direct Current Stimulation, Executive Dysfunction
Interventions: Anodal tDCS treatment, Cathodal tDCS treatment, Sham treatment, NIH Toolbox List Sorting Working Memory Test, NIH Toolbox Flanker Inhibitory Control and Attention Test, Grooved Peg Board Test, Buschke Selective Reminding Test; Device · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 8 Years to 215 Months
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Mild Cognitive Impairment (MCI)
Interventions: mentally stimulating activities; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 50 Years to 100 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Alzheimer Disease
Interventions: 18F-AV-1451; Drug
Lead sponsor: Tammie L. S. Benzinger, MD, PhD; Other
Eligibility: 65 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Post Traumatic Headache
Interventions: naratriptan HCl; Drug
Lead sponsor: Cady, Roger, M.D.; Individual
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Springfield, Missouri • Charlotte, North Carolina • Dallas, Texas

Conditions: Orofacial Myofunctional Disorders, Myo Munchee, Oral Motor Therapy, Maxillary Deficiency
Interventions: Chewing device only, Myo Munchee and Oral Motor Therapy Treatment, Oral Motor Therapy Treatment Arm; Device · Other
Lead sponsor: Myo Munchee (Operations) Pty Ltd; Industry
Eligibility: 3 Years to 5 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois

Conditions: Mild Cognitive Impairment
Interventions: Tailored Rhythmic Lighting Intervention, Placebo Rhythmic Lighting Intervention; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 55 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Menands, New York • New York, New York

Conditions: Depression
Interventions: Diazoxide, Placebo; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Mild Cognitive Impairment, Alzheimer Dementia (AD)
Interventions: Closed-loop TBS, Open-loop TBS; Device
Lead sponsor: University of Texas at Austin; Other
Eligibility: 18 Years to 90 Years
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Pelvic Floor Dysfunc, Chronic Constipation
Interventions: 7 inch Footstool for bowel movements, 9 inch Footstool for bowel movements; Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Cognitive/Functional Effects, Delirium, Depression, Lung Cancer, Radiation Toxicity
Interventions: vitamin E, donepezil hydrochloride, placebo; Dietary Supplement · Drug · Other
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 15
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 12 more

Conditions: Adverse Childhood Experiences, Sleep Disruption, Vascular Dysfunction, Endothelial Function (FMD)
Interventions: Cognitive Behavioral Therapy for Insomnia; Behavioral
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 29 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Mild Cognitive Impairment
Interventions: Project 3, Phase 2: Clinical Trial; Behavioral
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Tallahassee, Florida • Champaign, Illinois • New York, New York

Conditions: Chalazion, Dry Eye Syndromes
Interventions: LipiFlow System; Device
Lead sponsor: TearScience, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Hoffman Estates, Illinois • Boston, Massachusetts • Winchester, Massachusetts

Conditions: Bipolar Disorder, Cognitive Impairment
Interventions: Quetiapine XR, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Atlanta, Georgia • Durham, North Carolina

Conditions: Prostate Cancer
Interventions: Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls, Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Male only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Systemic Lupus Erythematosus
Interventions: Modafinil; Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: New York, New York

Conditions: Endometriosis
Interventions: 75 mg linzagolix tablet, 200 mg linzagolix tablet, Add-back capsule (E2 1 mg / NETA 0.5 mg), Placebo tablet to match 75 mg linzagolix tablet, Placebo tablet to match 200 mg linzagolix tablet, Placebo capsule to match Add-back capsule; Drug
Lead sponsor: Kissei Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 107
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 79 more

Conditions: Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions: Pemvidutide, Placebo; Drug · Other
Lead sponsor: Altimmune, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 9
States / cities: North Little Rock, Arkansas • Fountain Valley, California • Fresno, California + 6 more

Conditions: Delirium, Postoperative Cognitive Dysfunction
Interventions: Lumosity; Device
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 60 Years to 90 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Degeneration Spine, Cervical Radiculopathy, Cervical Stenosis, Cervical Spondylosis, Cervical Myelopathy, Dysphagia
Interventions: Sodium chloride gargle; Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Placebo, Sildenafil, Testosterone; Drug
Lead sponsor: Emotional Brain NY Inc.; Industry
Eligibility: 21 Years to 70 Years · Female only
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 14
States / cities: San Diego, California • Washington D.C., District of Columbia • Brooksville, Florida + 11 more

Search by objective public record fields.

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

High Intensity Exercise and Improving Physical Activity Among People With Neurologic Dysfunction

The Kidney's Response to Exercise in Heat, and the Impact of Vitamin B3 on This Response

Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL)

Effects of Mental Stimulation in Patients With Mild Cognitive Impairment

Evaluating the Relationship Between Tau PET Imaging and CSF Biomarkers of AD (Alzheimer Disease) in Humans

Naratriptan for the Treatment of Post Traumatic Headache Associated With Cognitive Dysfunction

Trial to Compare the Effects of Myo Munchee Therapy and Oral Motor Therapy (OMT) in Pediatric Patients to Treat Maxillary Deficiency and Orofacial Myofunctional Dysfunction (OMD).

Rhythmic Light Therapy for Alzheimer's Disease Patients

Does Enhanced Glutamate Transporter Function Produce Antidepressant Effects in People With Major Depression?

Closed-Loop Brain Stimulation as a Potential Intervention for Cognitive Decline

Footstool in Alleviating Symptoms of Evacuation Disorder

Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer

ACEs, CBT-i, and Cardiovascular Health

Digital Tools to Support Healthcare Decision Making

Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction

Quetiapine XR for Cognitive and Functional Disability in Clinically Stable Patients With Bipolar Disorder

Therapy for Erectile Dysfunction Adaptation of ACT for Compliance With an Erectile Rehabilitation Program

Memory and Attention Problems in Lupus: New Treatment Trial With Modafinil

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH

Prevention of Early Postoperative Decline

Salt Water Gargling on Swallowing Following ACDF

Lybrido for Female Sexual Dysfunction